Connection

Michael Hallek to Risk Factors

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Risk Factors.
Michael Hallek
Connection Strength
0.059
Risk Factors
  1. Chronic lymphocytic leukaemia. Lancet. 2018 04 14; 391(10129):1524-1537.
    View in: PubMed
    Score: 0.023
  2. Role and timing of new drugs in CLL. Hematol Oncol. 2017 Jun; 35 Suppl 1:30-32.
    View in: PubMed
    Score: 0.022
  3. Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. Bone Marrow Transplant. 2021 03; 56(3):716-719.
    View in: PubMed
    Score: 0.007
  4. [Individualized Treatment of Chronic Lymphocytic Leukemia (CLL)]. Dtsch Med Wochenschr. 2018 09; 143(18):1318-1324.
    View in: PubMed
    Score: 0.006
  5. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol. 2007 Jan; 136(1):63-72.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.